ABOUT THIS STUDY
- GD patients, male and female, 18 years or older
- Currently treated with enzyme replacement therapy for 5 years and more, with a stable unchanged dose in the previous 6 months
- Imaging features of significant residual bone disease defined as QCSI under 0.3 bone at risk
- Able to provide written informed consent
- Currently taking another experimental drug for any condition
- Presence of any medical, emotional, behavioral or psychological condition that in the
judgment of the Investigator would interfere with the patient's compliance with the
requirements of the study.
- Past exposure to Elelyso
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Fairfax, Virginia